FDA committee to consider recommending teprotumumab for thyroid eye disease

The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA will vote today on whether to recommend approval of a biologics license application for teprotumumab, an experimental human monoclonal antibody shown to dramatically reduce the most debilitating symptoms of Graves’ orbitopathy.
Teprotumumab (Horizon Therapeutics), an insulin-like growth factor-1 receptor inhibitor, is a fully human monoclonal antibody developed to address a significant unmet need in patients with thyroid eye disease, a condition most commonly associated with Graves’ hyperthyroidism. The drug blocks

Full Story →